

# Peter Orth

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6451326/publications.pdf>

Version: 2024-02-01

11  
papers

370  
citations

1307594

7  
h-index

1474206

9  
g-index

11  
all docs

11  
docs citations

11  
times ranked

567  
citing authors

#	ARTICLE	IF	CITATIONS
1	Design and discovery of C2-fluoroalkyl iminothiazine dioxides as BACE inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 56, 128463.	2.2	0
2	From Powders to Single Crystals: A Crystallographer's Toolbox for Small-Molecule Structure Determination. <i>Molecular Pharmaceutics</i> , 2022, 19, 2133-2141.	4.6	4
3	A chemoenzymatic strategy for site-selective functionalization of native peptides and proteins. <i>Science</i> , 2022, 376, 1321-1327.	12.6	22
4	Unprecedented Reversal of Regioselectivity during Methanolysis and an Interception of Curtius Rearrangement. <i>European Journal of Organic Chemistry</i> , 2021, 2021, 5073-5079.	2.4	0
5	Discovery of cell active macrocyclic peptides with on-target inhibition of KRAS signaling. <i>Chemical Science</i> , 2021, 12, 15975-15987.	7.4	26
6	From Screening to Targeted Degradation: Strategies for the Discovery and Optimization of Small Molecule Ligands for PCSK9. <i>Cell Chemical Biology</i> , 2020, 27, 32-40.e3.	5.2	44
7	Fused bi-heteroaryl substituted hydantoin compounds as TACE inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 3037-3042.	2.2	8
8	Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931) as a $\beta$ -Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 10435-10450.	6.4	126
9	Structure-Based Design of an Iminoheterocyclic $\beta$ -Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central $A\beta$ in Nonhuman Primates. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 3231-3248.	6.4	36
10	Iminopyrimidinones: A novel pharmacophore for the development of orally active renin inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 1592-1596.	2.2	7
11	Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor That Affords Robust CNS $A\beta$ Reduction. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 897-902.	2.8	97